Osel, Inc.

Other

Scios Inc.

Eli Lilly and Company

Qiang Xu

John A Lewicki

David A Simpson

Chia-Hwa Chang

Barbara Cordell

Theresa Li-Yun Chang

Yang Liu

Ziyang Zhong

Sheila P Little

Paul Andrew Hyslop

Edward Marion Johnstone

Yu-Wang Liu

Diana Hom Quon

Frauke Schimmöller

Xiaowen Liu

Steven Wyatt Queener

Tinggui Yin

Jun Wang

Steven Marc Paul

Kelly R Bales

Rosa Yu

Andrew Cheng

Qing Xia

Asha Naidu

Kirsten Essenmacher

An in-water suction cleaner includes a portable housing for disposing at water of a pool or tank, a motorized unit supported in the portable housing for vacuuming a suction cavity of the portable housing to suck the water in the suction cavity out of the portable housing through a fluid outlet of the portable housing so as to create a suction at a fluid inlet of the portable housing, a manual scrubbing arrangement detachably coupled at the fluid inlet of the portable housing for scrubbing pool or tank surfaces and for sucking the water into the suction cavity at the same time, and a filtering element replaceably disposed in the suction cavity for filtering the water from the fluid inlet to the fluid outlet through the suction cavity so as to ensure the water after filtered being discharged back to the pool or tank via the fluid outlet.

In-water suction cleaner

The present invention relates to methods and compositions forReplacement Therapy (LRT). Methods for improved stability and recovery of dried bacterial preparations are also provided.

[object Object]

The invention provides a naturally occurring strain ofwith advantageous characteristics. The strain colonizes mucosal surfaces, particularly vaginal surfaces. The strain is also capable of rapid growth in a number of conditions and is highly viable after desiccation. Moreover, the strain is capable of preventing and reducing pathogenic infection of vaginal mucosa.

The present invention relates tospecies recombinantly altered to express a biologically active protein. The invention also related to methods of providing the bacteria to the vagina.

Lactobacilli expressing biologically active polypeptides and uses thereof

Methods and compositions for targeting heterologous polypeptides to bacterial cell walls are provided.

Surface expression of biologically active proteins in bacteria

This disclosure relates to a modified version of cyanovirin-N protein and a transformedbacterium that is capable of recombinantly expressing this modified protein. Further disclosed are polynucleotide sequence encoding the modified cyanovirin-N protein, expression cassette that allows the expression of the modified protein, and method of make and use of the modified protein as well as the transformedbacterium. In addition, this disclosure describes two novel promoters originated from, which are capable of directing a high level of gene expression inbacteria. Also described are an expression cassette comprising one of the novel promoters, a genetically modifiedbacterium containing the expression cassette, a method for recombinant gene expression inbacteria using the novel promoters, and a method for delivery of proteins with desired biological activity to a mucosal surface in a human.

Modified cyanovirin-n polypeptide

The invention concerns a novel &#x3b2;-secretase, a method of partially purifying this novel &#x3b2;-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel &#x3b2;-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.

&#x3b2;-secretase and modulation of &#x3b2;-secretase activity

The invention concerns a novel &#x3b2;-secretase, a method of partially purifying this novel &#x3b2;-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel &#x3b2;-secretase has an estimated molecular weight of about 32&#x2013;39 kDa or 22&#x2013;26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5&#x2013;7.0.

The present invention provides a method of assaying for and arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing &bgr;-amyloid plaque burden by the administration of compounds that reduce apoE expression. The compounds used in the method of the invention may be: 1) inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase; 2) inhibitors of cholesterol biosynthesis; 3) inhibitors of protein isoprenylation, specifically geranylgeranylation; and/or 4) inhibitors of NF-&kgr;B activation or function. Assays for compounds with inhibit apoE expression from microglial cells are also disclosed.

Assay to identify compounds that alter apolipoprotein E expression

Growing community of inventors

Cupertino, CA, United States of America

Qiang Xu